RELATED NEWS
Life Sciences PE: The Misunderstood Opportunity
Christoph Broja, Partner at EQT, dismantled the myth that biotech is too risky for private...
No Fund. No Problem. The Rise of the Independant Sponsor
Christiaan de Lint of Headway Capital, made the case for one of private equity's fastest-growing...
Secondaries in 2026: The Active Allocator's Edge
Iyobosa Adeghe from Coller Capital, made the case for why sophisticated investors are increasingly...